Objective. One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage. We undertook this study to analyze data from a large clinical SLE cohort to compare patients achieving different levels of disease activity with respect to rates of long-term damage.
Methods. We analyzed data from 1,356 SLE patients in the Hopkins Lupus Cohort, followed up quarterly, with 77,105 person-months observed from 1987 to 2016. Three outcome measures were considered: clinical remission with no treatment, clinical remission on treatment, and lupus low disease activity state (LLDAS).
Results. Patients achieved LLDAS in 50% of their follow-up months. They achieved clinical remission with no treatment or clinical remission on treatment in only 13% and 27%, respectively, of their follow-up visits. The rates of damage consistently declined with increased percentage of prior time in either LLDAS or clinical remission on treatment. Spending a short proportion of prior time (<25%) in clinical remission on treatment was associated with a relatively low rate of damage compared to never achieving that condition (1.01 events per 10 person-years versus 1.82 events per 10 person-years; rate ratio 0.54, P < 0.0001). Those patients who experienced LLDAS at least 50% of the time had relatively low rates of damage (rate ratio 0.39-0.47, P < 0.0001).
Conclusion. LLDAS is an easier target to achieve than clinical remission on treatment and results in reduced risk of long-term damage. However, even a small percentage of time in clinical remission on treatment was associated with reduced damage.
Disease activity in systemic lupus erythematosus (SLE) is related to long-term organ damage (1, 2) . One complication in the choice of a "treat-to-target" outcome is the fact that some treatments for disease activity (e.g., corticosteroids) might themselves increase the rates of damage. Any dose of 6-12 mg/day increases major damage by 50% (3); doses of ≥10 mg/day increase cardiovascular events 2.4-fold, with a 20 mg daily dose increasing the risk 5.1-fold (4). There is uncertainty regarding the optimal combination of disease activity target and treatment target from the perspective of long-term damage risk.
One potential treatment target is "remission." A recent international collaborative effort, definitions of remission in SLE (DORIS), has developed a framework for defining remission (5) . This included subtypes of remission with or without abnormal serologic findings and with or without low levels of treatment.
An alternative approach has been taken by Franklyn et al (6) , who developed and validated criteria defining the lupus low disease activity state, or LLDAS. LLDAS is a less ambitious target than remission and allows for low levels of disease activity and treatment. LLDAS has been successfully applied post hoc to randomized clinical trials, including a trial of anifrolumab (an anti-interferon receptor monoclonal antibody) (7), proving that it is achievable in clinical research.
Clinical trials can rarely maintain randomization beyond 12 months, which is insufficient time to ascertain differences in organ damage. Thus, longitudinal cohorts have offered the best opportunity to determine if achievement of DORIS remission or LLDAS can reduce later organ damage, and by how much.
The Hopkins Lupus Cohort allowed us to study the association between time in various types of remission and/or LLDAS and long-term organ damage. We examined not just total organ damage, but individual organ damage, as well.
PATIENTS AND METHODS
Patients and data. The Hopkins Lupus Cohort is a prospective longitudinal single-center cohort of SLE patients ongoing since 1987. Patients met either the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria (8) or the classification criteria as defined by the American College of Rheumatology (ACR) (9) and as updated in 1997 (10) . Patients were seen by 1 rheumatologist at least every 3 months, with ascertainment of the physician's global assessment of disease activity (PhGA) (11) , the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index (SLEDAI) (12, 13) , and treatment. New organ damage was determined at each visit using the SLICC/ACR Damage Index (SDI) (14) . All patients provided informed consent, and the study was approved yearly by the Johns Hopkins University School of Medicine Institutional Review Board.
This analysis is based on cohort experience prior to October 2016. Only patients who provided at least 1 year of cohort participation were included. This included 1,356 SLE patients, of whom 55% were Caucasian, 38% African American, and 92% female. Their mean AE SD age at cohort entry was 38.2 AE 13.0 years. At cohort entry, 39% had had SLE for less than 1 year, 28% had had SLE for 1-5 years, and 33% had had SLE for more than 5 years. The median SLEDAI score at cohort entry was 2.0.
Definitions of remission and LLDAS. Based on the DORIS framework, for each visit, "clinical remission with no treatment" was defined as a PhGA of <0.5 and a SLEDAI score of 0, with no prednisone or immunosuppressant use. "Clinical remission on treatment" was the same but allowed prednisone at ≤5 mg/day and maintenance treatment with immunosuppressants. LLDAS was defined as a SLEDAI score of ≤4 with no SLEDAI scores for the renal, central nervous system, serositis, vasculitis, and constitutional components, no increase in any SLEDAI component since the previous visit, a PhGA of ≤1, and a prednisone dose of ≤7.5 mg/day. Immunosuppressants were allowed for LLDAS. Hydroxychloroquine treatment was allowed for all 3 definitions.
Statistical analysis. Using information collected at clinic visits, each visit for each patient was categorized as in remission or LLDAS based on the above definitions. Then, each month of follow-up for each patient was defined as in remission or LLDAS based on the status at the most recent clinic visit. For each follow-up month, we determined whether a new damage event occurred in that month. The months were then classified into subgroups defined by the percentage of prior months in remission or LLDAS, and the rate of damage events in each subgroup was calculated. For ease of interpretation, rates are reported per 10 person-years. Rate ratios and associated P values were estimated using logistic regression models fit by generalized estimating equations to account for the fact that each patient contributed multiple person-months.
The patients included in this analysis were followed up for a total of 77,105 person-months. All these months were used in computing the proportion of prior months in various disease states. In estimating rates of damage by prior history of disease states, we only used months of follow-up after the first year of cohort participation. In addition, we excluded any follow-up that occurred after a gap of more than 182 days between clinic visits. These exclusions resulted in an analysis of damage over 62,189 person-months of experience between 1988 and 2016. The mean number of person-months at risk per person was 46 and ranged from 1 to 292. Table 1 shows the proportion of person-months of follow-up in various states of disease activity. In 27% of the follow-up months, patients satisfied the definition of clinical remission on treatment. In contrast, in 50% of the follow-up months, patients satisfied the definition of LLDAS. Over 62,189 person-months of follow-up, we observed 595 new damage events. This corresponds to 1.15 events per 10 person-years. Table 2 shows the rates of damage in subgroups defined by percentage of prior cohort follow-up in remission or LLDAS. For each type of remission/LLDAS, the rates of damage decreased as the percentage of prior time in remission/LLDAS increased. Those who had clinical remission on treatment at any point in time but during less than 25% of their follow-up had substantially lower rates of damage than those who never had clinical remission on treatment (rate ratio 0.54, P < 0.0001). Patients with a small proportion of time in LLDAS did not experience a comparable reduction in damage rates. On the other hand, those patients who experienced LLDAS at least 50% of the time had relatively low rates of damage (between 0.75 and 0.88 events per 10 person-years). This LLDAS target was relatively easy to achieve (satisfied iñ 50% of the person-months of follow-up).
RESULTS
Because experience of prior damage is a strong predictor of future damage, we performed the analyses shown in Table 2 (13) damage, the pattern was similar to that shown in Table 2 (see Supplementary Table 1 ). For those months after a person has had 1 previous damage event, there was generally less of an association between damage and time spent in the categories of LLDAS and clinical remission on treatment (see Supplementary Table 2 ). Finally, for those months after a person has ≥2 previous damage events, there were strong associations between subsequent damage and prior LLDAS and remission, and even a small proportion of previous time in LLDAS was associated with Table 3) . Tables 3 and 4 show the effect of achieving LLDAS or clinical remission on treatment on individual organ damage items as defined by the SDI. Both LLDAS and clinical remission on treatment were associated with significantly reduced rates of musculoskeletal, renal, and osteoporosis damage and with significantly reduced rates of premature gonadal failure. LLDAS was also associated with a lower risk of diabetes mellitus, myocardial infarction, and seizures. There was no evidence of a relationship between either remission or LLDAS and risk of cataracts, malignancy, pulmonary damage, or eye organ damage. We found a substantially higher level of disease activity among African Americans than among Caucasians. Caucasians had 58% of follow-up (out of 41,860 months) in LLDAS and 32% in clinical remission on treatment. African Americans had only 41% of follow-up (out of 30,255 months) in LLDAS and 19% in clinical remission on treatment (P < 0.0001 for each difference). This increased level of disease activity was not explained by socioeconomic status as represented by education (P < 0.0001 for each comparison after adjustment for years of education). Table 5 shows the relationship between damage and LLDAS or clinical remission on treatment separately by ethnicity. Both in Caucasians and in African Americans, a reduced rate of damage was strongly associated with LLDAS or clinical remission.
DISCUSSION
This is the largest study (based on number of patients and duration of follow-up) of DORIS remission and LLDAS as predictors of organ damage. Because patients were followed up by protocol quarterly and all indices were completed by 1 rheumatologist, we were able to reduce variation and to avoid biases of different followup intervals based on disease activity. Our analysis used percentage of months (rather than "consecutive years") to reflect that over years of follow-up most patients experience flares, temporarily leaving remission or LLDAS. Also, unlike previous analyses, we examined the association between prior experience of remission or LLDAS and subsequent damage, rather than the association between remission or LLDAS and damage that occurred in the same interval of time.
First, we showed that even a small percentage of time (<25%) in DORIS clinical remission with minimal treatment led to an~50% reduction in organ damage. A 
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longer period of time in LLDAS was required to achieve a comparable reduction in organ damage. Second, we showed that patients who satisfied the criteria for LLDAS over 50% of their follow-up achieved a substantial reduction in damage. This is noteworthy since this may be an easier target to achieve. Fully 50% of the follow-up time of our cohort satisfied this condition. The fact that those who achieve LLDAS >50% of the time have just as low risk as those who achieve the more stringent targets of clinical remission >50% may be due to sampling variability. However, if this association is real, it has implications regarding the treatment target for those with relatively good disease control.
Third, we showed that being in LLDAS >50% of the time did not prevent all types of organ damage. In particular, it prevented musculoskeletal, cerebrovascular accident, and renal damage, osteoporotic fractures, and myocardial infarction. There was no evidence that time in LLDAS prevented cataracts (likely as even low-dose prednisone use contributes to cataracts). It did not prevent pulmonary fibrosis or pulmonary hypertension. It did not prevent cognitive impairment. Thus, much as we believe that reduction in both disease activity and prednisone is our optimum clinical outcome, we are obviously missing some additional factors that lead to important organ damage.
Fourth, we found that African Americans have substantially more disease activity than Caucasians even after adjustment for years of education, leading to a decreased chance of achieving either LLDAS or clinical remission. However, the same relationship holds true that achieving LLDAS or clinical remission leads to a significant reduction in organ damage. This is consistent with a previous analysis of our cohort in which we showed that rates of damage were significantly higher among African American patients, but this disparity was substantially reduced after adjustment for disease activity and other variables (1).
Our findings are consistent with recent studies of new definitions of LLDAS and remission. In their seminal study on LLDAS, Franklyn et al found that patients in their cohort with more than 50% of their follow-up in LLDAS had an average increase in damage score of 0.57 points less than those with more disease activity during an average of 3.9 years of follow-up per person. Their cohort had somewhat more disease activity than ours, with an average of only 39% of follow-up in LLDAS compared to 50% in ours. In 293 Italian Caucasian patients, patients with 2 consecutive years in LLDAS had less damage accrual (15) . In 183 patients with a median follow-up of 5 years, either LLDAS or remission in >50% of observable visits was associated with reduced organ damage (16) . However, ours is the first study to show a comparison of DORIS remission and LLDAS, the first to include a large number of African Americans, and the first to include damage to individual organs (and not just total damage). Our findings on the rate of achievement of LLDAS and remission and the number of subsequent damage events might be useful to those planning clinical trials of the impact of reducing disease activity on damage. In clinical trials, LLDAS seems to be a very reasonable outcome measure, with trials already showing that it is achievable. In clinical practice, remission would remain the best (but hard to achieve) goal.
A limitation of our study is that it is based on disease activity measures and damage accrual over a 30-year period. The relationship between disease activity, treatment, and damage accrual may be somewhat different today given new approaches to patient management.
Another limitation of analyses of observational studies such as ours or those cited above is that they cannot establish a causal relationship between disease activity and damage. Thus, for example, increased SLE disease activity might reflect an unknown underlying condition that also leads to increased risk of damage. If that is the case, then reducing disease activity would not result in a decline in damage risk to the same degree observed in these studies.
Just as not all types of SLE damage are associated with SLE disease activity, not all manifestations of SLE disease activity are associated with damage. Therefore, an alternative to setting the target of overall low disease activity would be to target specific types of disease activity that are associated with specific types of damage. These relationships need to be identified. For example, in previous work, we have tried to identify specific risk factors for cardiovascular events (4), cataracts (17) , seizures (18) , and depression (19) .
In conclusion, DORIS remission on treatment even for a small percentage of visits reduces later organ damage. LLDAS 50% of the time reduces organ damage by~50%. However, not all types of individual organ damage are reduced.
